Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
That is well above the 50% efficacy required by U.S. regulators. Europe’s drug regulator has said it will not set a minimum level of efficacy for potential vaccines. This is in part because the number of participants is greatly reduced in a sub-group - making it harder to be confident that a finding is not just down to chance differences or similarities among participants.
The regulatory process has nonetheless been clouded, according to experts, who note crucial gaps in the data AstraZeneca has made public so far.
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔